GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kyongbo Pharmaceutical Co 214390.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

4,800

-3.90%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩264.10bn

FY2016FY2025

Net income

₩182.3m

FY2016FY2025

Free cash flow

−₩34.16bn

FY2016FY2025

Shareholders' equity

₩145.74bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩264.10bn₩238.56bn₩216.36bn₩196.26bn₩170.66bn₩215.29bn₩191.71bn₩201.34bn₩191.66bn₩186.73bn
Gross profit₩102.30bn₩89.27bn₩63.08bn₩44.42bn₩35.36bn₩52.46bn₩40.72bn₩49.26bn₩54.62bn₩44.10bn
Research and development₩18.16bn₩12.17bn₩3.65bn₩3.08bn₩5.05bn₩6.24bn₩1.42bn₩769.8m₩765.4m₩1.48bn
Operating income₩4.70bn₩9.12bn₩5.54bn₩1.39bn−₩4.60bn₩5.68bn₩7.49bn₩18.16bn₩24.59bn₩16.65bn
Net income₩182.3m₩4.64bn₩2.97bn₩610.6m−₩7.50bn₩9.40bn₩5.29bn₩13.12bn₩17.96bn₩12.71bn
Diluted earnings per share7.59193.19123.8625.54-313.52393.38221.08548.63751.39531.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩319.54bn₩283.89bn₩266.31bn₩240.54bn₩236.98bn₩253.24bn₩237.82bn₩221.62bn₩204.87bn₩203.74bn
Cash and short-term investments———₩7.22bn₩4.29bn₩20.98bn₩6.77bn₩4.99bn₩6.40bn₩4.58bn
Total liabilities₩173.80bn₩137.73bn₩121.92bn₩96.84bn₩91.28bn₩97.18bn₩88.65bn₩72.61bn₩63.36bn₩74.33bn
Debt₩24.00bn—₩45.0m₩64.51bn₩56.59bn₩63.27bn₩56.42bn₩42.57bn₩28.83bn₩41.08bn
Shareholders' equity₩145.74bn₩146.15bn₩144.38bn₩143.70bn₩145.70bn₩156.06bn₩149.16bn₩149.01bn₩141.51bn₩129.40bn
Shares outstanding24m24m24m24m24m24m24m24m24m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩7.46bn₩149.1m₩4.84bn₩10.13bn₩17.97bn₩20.80bn₩23.67bn−₩1.14bn₩25.81bn₩25.33bn
Capital spending−₩41.61bn−₩13.18bn−₩10.88bn−₩13.18bn−₩18.32bn−₩12.44bn−₩23.25bn−₩8.19bn−₩7.40bn−₩19.68bn
Free cash flow−₩34.16bn−₩13.03bn−₩6.03bn−₩3.06bn−₩355.6m₩8.36bn₩422.0m−₩9.33bn₩18.41bn₩5.64bn
Dividends paid−₩1.20bn−₩1.20bn−₩1.20bn−₩1.20bn−₩2.39bn−₩2.39bn−₩4.78bn−₩5.98bn−₩4.78bn−₩6.57bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩75.22bn₩66.13bn₩71.22bn₩66.99bn₩65.31bn₩60.59bn₩59.31bn₩58.23bn
Gross profit₩28.68bn₩27.44bn₩26.75bn₩24.60bn₩26.90bn₩24.06bn₩23.48bn₩21.68bn
Operating income₩930.3m₩712.8m₩515.5m₩474.5m₩2.41bn₩121.2m₩2.97bn₩3.16bn
Net income₩2.97bn−₩529.7m−₩432.7m₩3.03bn−₩1.73bn−₩694.8m₩1.75bn₩1.08bn
Diluted earnings per share123.83-22.06-18.02126.25-72.21-28.9372.9445.03
Cash from operations−₩565.0m₩1.79bn₩6.22bn₩4.51bn−₩1.28bn−₩1.99bn₩5.67bn−₩1.34bn
Capital spending−₩16.92bn−₩15.55bn−₩7.81bn−₩17.04bn−₩10.96bn−₩5.80bn−₩2.91bn−₩3.42bn
Free cash flow−₩17.49bn−₩13.76bn−₩1.59bn−₩12.53bn−₩12.25bn−₩7.79bn₩2.76bn−₩4.76bn
Total assets₩367.57bn₩339.07bn₩319.54bn₩316.49bn₩312.37bn₩287.71bn₩283.89bn₩279.62bn
Debt₩24.00bn₩24.00bn₩24.00bn—————
Shareholders' equity₩146.99bn₩144.29bn₩145.74bn₩145.28bn₩142.02bn₩144.09bn₩146.15bn₩145.73bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.4%4.2%4.0%
Operating income50.0%-3.7%-15.6%
Net income-33.2%-54.6%-39.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin38.1%32.7%29.7%27.7%
Operating margin2.7%2.3%1.7%5.1%
Net margin1.0%0.9%0.8%3.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings—32.267.7391.5-34.341.637.418.716.726.3
Price to sales0.50.60.91.21.51.81.01.21.61.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2024.

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Paid in the year100.0050.0050.00100.00100.00200.00250.00200.00

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.